Novel Systemic Therapies for Advanced Gastric Cancer
Authors:
Open Access
- 1 January 2018
- journal article
- review article
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 18 (1) , 1-19
Abstract
Gastric cancer (GC) is the second leading cause of cancer mortality and the fourth most commonly diagnosed malignant diseases. While continued efforts have been focused on GC treatment, the introduction of trastuzumab marked the beginning of a new era of target-specific treatments. Considering the diversity of mutations in GC, satisfactory results obtained from various target-specific therapies were expected, yet most of them were unsuccessful in controlled clinical trials. There are several possible reasons underlying the failures, including the absence of patient selection depending on validated predictive biomarkers, the inappropriate combination of drugs, and tumor heterogeneity. In contrast to targeted agents, immuno-oncologic agents are designed to regulate and boost immunity, are not target-specific, and may overcome tumor heterogeneity. With the successful establishment of predictive biomarkers, including Epstein-Barr virus pattern, microsatellite instability status, and programmed death-ligand 1 (PD-L1) expression, as well as ideal combination regimens, a new frontier in the immuno-oncology of GC treatment is on the horizon. Since the field of immuno-oncology has witnessed innovative, practice-changing successes in other cancer types, several trials on GC are ongoing. Among immuno-oncologic therapies, immune checkpoint inhibitors are the mainstay of clinical trials performed on GC. In this article, we review target-specific agents currently used in clinics or are undergoing clinical trials, and highlight the future clinical application of immuno-oncologic agents in inoperable GC.Keywords
This publication has 110 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)British Journal of Cancer, 2010
- Meta-analysis Shows That Prevalence of Epstein–Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic LocationGastroenterology, 2009
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancerBritish Journal of Cancer, 2009
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001